Log in

BiomX Stock Forecast, Price & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average Volume3,395 shs
Market Capitalization$140.03 million
P/E RatioN/A
Dividend YieldN/A
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.00 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Phone972 7 23942377



Sales & Book Value

Annual SalesN/A
Book Value$3.83 per share


Net Income$-20,560,000.00


Market Cap$140.03 million
Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive PHGE News and Ratings via Email

Sign-up to receive the latest news and ratings for PHGE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

BiomX (ARCA:PHGE) Frequently Asked Questions

What stocks does MarketBeat like better than BiomX?

Wall Street analysts have given BiomX a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BiomX wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of BiomX's key competitors?

Who are BiomX's key executives?

BiomX's management team includes the following people:
  • Mr. Jonathan Eitan Solomon MBA, CEO & Director (Age 43, Pay $615.4k)
  • Mr. Assaf Oron, Chief Bus. Officer (Age 46, Pay $346.83k)
  • Dr. Sailaja Puttagunta, Chief Medical Officer (Age 52, Pay $495.8k)
  • Prof. Rotem Sorek, Scientific Founder
  • Dr. Eran Elinav, Scientific Founder
  • Prof. Timothy K. Lu, Scientific Founder
  • Ms. Marina Wolfson, VP of Fin. & Operations and CFO (Age 36)
  • Noel Kurdi, VP of Investor Relations & Strategy
  • Dr. Merav Bassan Ph.D., Chief Devel. Officer (Age 55)
  • Dr. Inbar Gahali-Sass, VP of Platform R&D

What is BiomX's stock symbol?

BiomX trades on the ARCA under the ticker symbol "PHGE."

How do I buy shares of BiomX?

Shares of PHGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

How big of a company is BiomX?

BiomX has a market capitalization of $0.00. The company earns $-20,560,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. BiomX employs 73 workers across the globe.

What is BiomX's official website?

The official website for BiomX is www.biomx.com.

How can I contact BiomX?

The company can be reached via phone at 972 7 23942377.

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.